// App-Quantinova.ai

628 : Trial in progress: phase I dose-escalation study of VSV-GP (BI 1831169) monotherapy and with ezabenlimab (BI 754091) in patients with locally advanced or metastatic solid tumors

Researchers

Presenter

  • Mercedes Porosnicu

Principal Investigators

  • Anne-Marie Quinson

  • Abi MacKay

  • Stephan Luecke

  • Ulrich M Lauer

Medical Centers

  • Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach, Germany

  • Boehringer Ingelheim Ltd, Bracknell, UK

  • Wake Forest School of Medicine, Winston-Salem, NC

  • University Hospital Tübingen, Rheumatology, Tübingen, Germany

Locations

  • Germany

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Interferon

Outcome

  • N/A

Study Design

  • Open Label

  • Expansion Study

  • Dose Escalation

Phase

  • I

Study Id's

  • NCT05155332

Sponsors

  • Boehringer Ingelheim International GmbH

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved